Takeda Announces U.S. FDA Accepts NDA And Grants Priority Review For Rusfertide As A Potential First-In-Class Therapy For Polycythemia Vera

Takeda Pharmaceutical

02/03/2026 07:02

March 2 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:

TAKEDA PHARMACEUTICAL CO LTD: TAKEDA ANNOUNCES U.S. FDA ACCEPTS NDA AND GRANTS PRIORITY REVIEW FOR RUSFERTIDE AS A POTENTIAL FIRST-IN-CLASS THERAPY FOR POLYCYTHEMIA VERA

TAKEDA PHARMACEUTICAL CO LTD: IMPACT ON TAKEDA'S FINANCIAL RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2026 (FY2025), FOLLOWING ACCEPTANCE OF NDA, IS IMMATERIAL

Source text: ID:nTSob8bf58

Further company coverage: 4502.T

 (Reporting by Tokyo Newsroom)

 ((+81345201189;))